Neuroendocrine Tumors
Research on neuroendocrine tumors (NETs) including carcinoid tumors, pancreatic NETs, and gastroenteropancreatic NETs. Studies evaluate tumor control, symptom management, and survival outcomes.
Quick Answer
What it is
Research on neuroendocrine tumors (NETs) including carcinoid tumors, pancreatic NETs, and gastroenteropancreatic NETs. Studies evaluate tumor control, symptom management, and survival outcomes.
Key findings
- Grade A: Tumor Progression (NETs) (Octreotide (Sandostatin))
- Grade A: Carcinoid Syndrome Symptoms (Octreotide (Sandostatin))
- Grade A: VIPoma Diarrhea (Octreotide (Sandostatin))
Safety
- 79% reduction in progression/death risk.
- CLARINET trial: 53% reduction in disease progression risk (HR 0.47, P<0.001).
ℹ️ Quick Facts
Quick Facts: Neuroendocrine Tumors
- Supplements Studied:3
3 supps · 12 outcomes
Detailed Outcomes
|
A
Tumor Progression (NETs)
PROMID trial showed median time to tumor progression of 14.3 months vs 6 months placebo (HR 0.34, P<0.001) in metastatic midgut NETs.
large↓Improves
A
Carcinoid Syndrome Symptoms
Over 70% of patients achieve significant improvement or resolution of diarrhea and flushing with octreotide LAR treatment.
large↓Improves
A
VIPoma Diarrhea
FDA-approved for watery diarrhea associated with VIP-secreting tumors, with significant symptom improvement.
large↓Improves
B
Survival (NETs)
Retrospective data suggest improved 5-year survival (67% vs 18% historical controls) in advanced GEP-NETs treated with octreotide.
moderate↑Improves
A
Progression-Free Survival
NETTER-1: 65.2% PFS rate at month 20 vs 10.8% control. 79% reduction in progression/death risk. Median PFS not reached vs ~8 months control. Doubled median PFS from 9 to 23 months in GEP-NETs.
large↑Improves
A
Overall Survival
Final NETTER-1: Median OS 48.0 months vs 36.3 months control (11.7 month benefit). HR 0.84. Clinically meaningful survival advantage despite P=0.30 due to crossover.
large↑Improves
A
Objective Response Rate
NETTER-1: Significantly higher ORR with 177Lu-DOTATATE vs control. 16% ORR including complete responses in ERASMUS study subset. Tumor shrinkage correlates with improved outcomes.
large↑Improves
A
Quality of Life
Time to QoL deterioration: 28.8 months vs 6.1 months (global health). Physical functioning: 25.2 months vs 11.5 months. Clinically significant improvements maintained long-term.
large↑Improves
A
Progression-Free Survival (NETs)
CLARINET trial: 53% reduction in disease progression risk (HR 0.47, P<0.001). 65.1% vs 33.0% PFS at 24 months. Median PFS not reached vs 18 months placebo.
large↑Improves
A
Tumor Stabilization (NETs)
Stable disease rates of 15-89% in clinical trials. Phase II studies show significant antitumor effects with disease control in majority of patients.
large↑Improves
A
Carcinoid Syndrome Symptoms
FDA-approved for symptomatic control of flushing and diarrhea associated with carcinoid syndrome. Significant QOL improvement in symptomatic patients.
large↓Improves
A
VIPoma Symptoms
Effective for controlling watery diarrhea and electrolyte disturbances in VIP-secreting tumors.
large↓Improves